

MULTIPLE CRANIAL NERVE BLOCKS FOR THE TRANSITIONAL TREATMENT OF CHRONIC HEADACHES

¹Sarah Miller MBBS, MRCP, ¹Susie Lagrata MSc and ¹Manjit Matharu FRCP, PhD

¹Headache Group, Institute of Neurology and The National Hospital for Neurology and
Neurosurgery, Queen Square, London, UK

Prepared For: Cephalgia

Title Character Count: 71

Abstract: 195

Body: 2816

Tables: 4

Figures: 2

References: 27

Corresponding Author:

Dr MS Matharu

Senior Lecturer and Honorary Consultant Neurologist

Headache Group, Institute of Neurology and The National Hospital for Neurology and

Neurosurgery, Queen Square, London WC1N 3BG

Email: m.matharu@uclmail.net

Tel: +447595900535

Fax: +44 7092120797

Key words

Nerve block, Migraine, Cluster headache, New daily persistent headache, Paroxysmal hemicrania, Short lasting unilateral neuralgiform attack disorders

ABSTRACT

Background

Multiple cranial nerve blocks of the greater and lesser occipital, supraorbital, supratrochlear and auriculotemporal nerves are widely used in the treatment of primary headaches. We present efficacy and safety data for these procedures.

Methods

In an uncontrolled open-label prospective study, 119 patients with chronic cluster headache, chronic migraine, short lasting unilateral neuralgiform attack disorders, new daily persistent headaches, hemicrania continua and chronic paroxysmal hemicrania were examined. All had failed to respond to greater occipital nerve blocks. Response was defined as a 50% reduction in either daily attack frequency or moderate-to-severe headache days after two weeks.

Results

The response rate of the whole cohort was 55.4%: chronic cluster headache 69.2%, chronic migraine 49.0%, short lasting unilateral neuralgiform attack disorders 56.3%, new daily persistent headache 10.0%, hemicrania continua 83.3% and **chronic** paroxysmal hemicrania 25.0%. Time to benefit was between 0.50 and 33.58 hours. Benefit was maintained for up to four weeks in over half responders in all groups except chronic migraine and paroxysmal hemicrania. Only minor adverse events were recorded.

Conclusion

Multiple cranial nerve blocks may provide an efficacious, well tolerated and reproducible transitional treatment for chronic headache disorders when greater occipital nerve blocks have been unsuccessful.

INTRODUCTION

Patients with primary headaches often complain of pain involving both the frontal (trigeminal innervation) and posterior (occipital nerves innervation) regions. This is due to the anatomical link between cervical and trigeminal afferents onto neurones within the trigeminocervical complex (TCC)¹. Peripheral nerve blocks targeting the occipital or trigeminal nerve branches of the scalp used in the treatment of headache are believed to exert effects via the TCC².

Peripheral nerve blocks provide prompt relief for patients with headache disorders. Their benefit has been shown to last beyond the period of local anaesthesia^{3,4}. The common target for peripheral nerve blocks is the greater occipital nerve (GON). However, other nerves innervating the scalp including the lesser occipital nerve (LON) and numerous branches of the trigeminal nerve such as the supratrochlear (STN), supraorbital (SON), and auriculotemporal (ATN) nerves can also be targeted.

The outcomes of greater occipital nerve blocks (GONB) have been widely produced in open-label studies in cluster headache^{3,5-8,6,7}, chronic migraine^{3,9} (CM), hemicrania continua (HC)^{3,10-12}, short lasting unilateral neuralgiform headache attacks^{3,13,14} and chronic paroxysmal hemicrania^{3,11} (CPH). Controlled trials are few but have been performed in cluster headache^{15,16} and migraine¹⁷⁻²⁰.

The use of blocks of multiple occipital and trigeminal nerve branches has not been well explored. We wished to explore the efficacy and safety of multiple cranial nerve blocks (MCNB) consisting of the GON, LON, SON, STN and ATN in patients with chronic headaches.

METHODS

Standard protocol approvals, registrations, and patient consents

This study received ethics approval from the Northwick Park Hospital NHS Research Ethics Committee. All patients provided written consent.

Patients

Consecutive patients with chronic headaches receiving MCNB **as part of their routine clinical care** at the National Hospital for Neurology and Neurosurgery, London, between May 2010 and September 2015 were assessed. Patients were diagnosed according to the International Classification of Headache Disorders (2nd edition)²¹. **Where multiple phenotypes existed, each met the relevant criteria. All patients with CPH or HC had had documented positive indomethacin tests but were unable to continue with indomethacin long term due to side effects or medical co-morbidities.** Patients were offered MCNB if previous GONB were unsuccessful or efficacy faded with repeated injections (Table 1).

Multiple Cranial Nerve Block Procedure

Injections were undertaken by **three headache specialist nurses**. The MCNB protocol involved a 50:50 mixture of 1ml lidocaine 2% and 1ml bupivacaine 0.5% for the SON, ATN, STN and LON, and 2ml 80mg methylprednisolone, 1ml 2% lidocaine and 1ml 0.5% bupivacaine for the GON. The amount injected was dependent on the procedure being unilateral or bilateral (Table 2). **Repeated injections were employed on the basis of clinical need and were given a minimum of three months apart.**

Figure 1 illustrates the injection sites. Localisation of the nerves was as follows:

Greater occipital nerve: at a point lying on the medial third of a line drawn between the occipital protuberance and mastoid process.

Lesser Occipital nerve: at a point lying two-thirds of the way on the line drawn between the occipital protuberance and mastoid process

Supratrochlear nerve: at a point just above the superomedial aspect of the orbit

Supraorbital nerve: at a point just above the supraorbital notch (mid-pupillary line)

Auriculotemporal nerve: first injection at a point 1-1.5cm above the root of the helix of ear; second injection 1-1.5cm in front of first injection site; third injection 2-3cm above upper tip of ear; fourth injection 2-3cm anterior to the third; fifth injection 2-3cm anterior to the fourth. If procedure is unilateral then a sixth injection is placed 2-3cm above the fourth.

The procedure took approximately 10 minutes to complete. As this procedure was offered as part of a patient's routine clinical care, changes in preventative medication were allowed as was the use of acute medication.

The maximum safe dose for infiltration or subcutaneous injections of lidocaine is 4.5mg/kg per dose. A 70kg adult can therefore have lidocaine 315mg infiltrated. In this study we infiltrated a total lidocaine dose of 220-240mg. The maximum safe dose for infiltration or subcutaneous injections of bupivacaine is 175mg per dose. In this study we infiltrated a total bupivacaine dose of 40-45mg.²²

Data Collection

Data was collected prospectively using headache diaries and entered onto a clinical database (Microsoft Excel, Microsoft Corporation, Redmond, WA, USA.). Patients kept prospective headache diaries for one month before and after MCNB. Where multiple phenotypes existed, patients were asked to keep separate diaries for each pain type. Average values of all headache measures were calculated for the two weeks prior to and after MCNB as well as weeks 3-4.

Collected data included patient demographics, headache phenotype, headache days (any day on which pain was recorded²³), moderate-to-severe headache days (days on which verbal rating scale of pain was four or more lasting at least four hours ²³), daily attack frequency, average daily pain/attack severity, average daily pain/attack duration and adverse events.

Primary outcome measure was the number of patients responding to treatment. Response was defined as a 50% or more reduction in mean moderate-to-severe headache days (for CM, NDPH and HC) or attack frequency (for CCH, SUNCT/SUNA and CPH) over the first two-weeks. Secondary outcomes included changes in headache days, pain/attack duration, daily pain/attack intensity, pain free days over the first two-weeks and the same measurements after weeks three and four. Total duration of effect and total pain free days were collated as was information on repeated procedures. Information on these longer-term outcomes was obtained and recorded during routine follow-up clinics.

Statistics

Continuous variables are summarized using mean, standard deviation and range, while categorical variables were summarized with percentages. Mean values pre- and post-treatment were compared using paired t-tests. Statistical significance level was set at the 95% level (p=0.05). Data was processed using IBM SPSS Statistics version 22 (IBM Corp. Int.)

RESULTS

Demographics

A total of 119 patients receiving initial MCNB were analysed with 137 headache phenotypes treated (17 patients documenting multiple phenotypes on separate diaries). The mean age of

the whole group was 48.51 years (± 12.13) and 55 patients (46.2%) were male. Phenotypes included CCH (43.7%), CM (41.2%), short lasting unilateral neuralgiform attack disorders (13.4%), NDPH with migrainous features (8.4%), HC (5.0%) and CPH (3.4%). Patients were complex and many had failed multiple medications prior to MCNB. The breakdowns of headache diagnosis and demographics are shown in Table 1.

Efficacy

The efficacy of response was determined on the basis of the average attack frequency (for cluster headache, short lasting unilateral neuralgiform attack disorders and paroxysmal hemicrania) or moderate-to-severe headache days over the first two weeks. Of the 137 headaches treated, 76 (55.4%) showed a positive response. The breakdown of response rates by phenotype is shown in Figure 2A.

Chronic Cluster headache (see Table 3 and Table 4)

The responder rate in CCH at two weeks was 69.2% (36/52). In responders ($n=36$), mean change in daily attack frequency was reduced by 3.33 (95% CI 2.78, 3.89) or 81.8% (± 19.93) ($p < 0.001$) and the mean number of pain-free days increased by 7.31 days (± 5.98) ($p < 0.001$). After weeks 3-4, 88.9% (32/36) of responders still exhibited a positive effect. Mean time to response was 22.47 hours (± 26.63). Significant improvements were also seen in attack severity and duration. Total reported time of benefit was 57.11 days (± 47.70) and total number of reported pain-free days post-MCNB was 29.69 days (± 48.66). Mean subjective benefit in responders was 69.6% (± 30.00). Results at four weeks are shown in table 4.

Chronic migraine (see Table 3 and Table 4)

The response rate in CM at two weeks was 49.0% (24/49). In responders (n=24), moderate-to-severe headache days reduced by 10.04 (95% CI 8.61, 11.46) ($p<0.001$). Average pain-free days over the first two weeks was 4.74 (± 5.33) ($p<0.001$). Significant improvements were seen in the other measures. After the final two weeks, 54.2% (13 patients) were still recording a response. Time to response was 33.58 hours (± 41.15), reported duration of benefit was 47.12 days (± 23.69) and total reported pain-free days after the procedure was 6.33 (± 9.00). Mean subjective benefit in responders was 59.95% (± 35.44). Results at four weeks are shown in table 4.

Short lasting unilateral neuralgiform headache attack disorders (see Table 3 and Table 4)

Response rate at two weeks in SUNCT/SUNA was 56.3% (9/16). In responders (n=9), attack frequency reduced by 95.7% (± 7.36) to 0.33 (± 0.50) ($p=0.003$). Pain free days were 8.78 (± 6.18) at two weeks compared to zero at baseline ($p=0.003$). Significant improvements were observed in attack severity ($p<0.001$) but not duration ($p=0.068$). At week four, all nine patients were still exhibiting response. Time to benefit was 29.89 hours (± 28.22), total reported benefit was 68.33 days (± 70.22) and total number of pain free days reported was 11.89 (± 14.36). Mean estimated improvement in responders was 67.7% (± 39.22). Results at four weeks are shown in table 4.

New daily persistent headache with migrainous features (NDPH) (see Table 3 and Table 4)

In the NDPH group, only one patient from ten (10.0%) showed response after two weeks. This patient reported a 50.0% reduction in moderate-to-severe headache days from 14.00 to 7.00 but still had daily headaches. They did not report meaningful change in daily pain duration or

severity. At week four, the patient had returned to baseline. Time to response was 24.00 hours, duration of benefit was 14.00 days and the patient did not report any pain free days post-MCNB. Results at four weeks are shown in table 4.

Hemicrania continua (see Table 3 and Table 4)

Response rate in the HC group was 83.3% (5/6) after two weeks. Responders (n=5) showed a mean reduction of 11.20 (95%CI 6.35, 16.04) moderate-to-severe headache days (p=0.003). Mean pain free days after two weeks was 11.00 (± 2.82) compared to 0.2 (± 0.45) (p=0.001). Significant improvements were seen in all other outcome measures. At week four, 80.0% (n=4) still showed a clinical response. Time to benefit was 24.80 hours (± 15.59), duration of benefit was 61.80 days (± 33.41) and total pain-free days post-procedure was 41.80 days (± 45.49). Estimated benefit in responders was 96.0% (± 8.94). Results after four weeks are shown in table 4.

Chronic paroxysmal hemicrania (see Table 3 and Table 4)

The response rate in CPH was 25.0% (1/4). In the single responder, the average daily attack frequency reduced to zero and the patient reported nine pain free days. After week four, the patient still showed a positive response. Estimated improvement in responders was 95.0%. Time to benefit was 0.50 hours, total duration of benefit was 40.00 days and total number of pain free days in this time was 20.00. Results after four weeks are shown in table 4.

Reproducibility of MCNB response

The mean number of procedures undertaken and the response rate of repeated MCNB in each headache group is shown in Figure 2B. **Of the 76 patients with an initial response, 45 (56.3%) went on to have at least one further MCNB. The average time between procedures was 6.27 months (± 7.42).** The average duration of successful repeated procedures was not significantly different from the first MCNB in CCH (52.88 vs 50.54 days, $p=0.480$), CM (37.82 vs 40.82 days, $p=0.582$), SUNCT/SUNA (37.50 vs 37.00, $p=0.944$) or HC (70.25 vs 52.50, $p=0.229$). Repeated MCNBs were not conducted for any PH or NDPH patients.

Adverse events (see Table 1)

In the 24-hours post procedure nine patients (7.5%) reported side effects: dizziness in 7 (5.8%), blurred vision in 1 (0.8%) and injection site tenderness in 1 (0.8%). Adverse events were reported up to one-month in 17 (14.2%) patients: injection site tenderness 7 (5.8%), transient worsening of headaches 3 (2.5%), nausea 3 (2.5%), neck pain 2 (1.6%) and one each of blurred vision (0.8%) and numbness over injection sites (0.8%). All adverse events were transient and resolved fully without treatment.

DISCUSSION

This is the first large series to examine the potential use of MCNB as a transitional treatment for chronic headache. Patients had a protracted history and had failed to benefit from, or had reducing efficacy from GONB. In such a group, the choice of alternative transitional treatments is limited. Oral steroids can be considered in CCH but have potentially serious adverse events, intravenous (IV) dihydroergotamine (DHE) may be useful but is increasingly difficult to source in the UK and both IV DHE and IV lidocaine require a hospital admission.

Multiple cranial nerve blocks appear to offer a valuable and potentially efficacious treatment option in such patients. Of the 137 headaches treated, 55.4% showed a positive response after two weeks. The response rates by phenotype were CCH 69.2%, CM 49.0%, SUNCT/SUNA 56.3%, NDPH 25.0%, HC 83.3% and CPH 10.0%. The benefit was maintained at four weeks in over half of original responders in CCH, SUNCT and HC. Significant improvements were seen in pain free days, attack frequency, moderate-to-severe headache days, pain duration and severity. Benefit seemed to be sustained for weeks in those that showed response except for NDPH where benefit lasted only two weeks in a single patient.

As this was a study conducted in real life clinical setting, patients could have had concurrent changes to their preventative medications whilst receiving a MCNB. At the time of MCNB, 60 patients (50.4%) had medication doses changed. However, we would argue that given that there is a considerable delay in the time to effect of preventative medication and that drugs being reduced had proved to be ineffective, allowing medication alterations was unlikely to have influenced the data collected within four weeks of any medication change. The MCNB are used as a transition treatment, often whilst waiting for a preventative to take effect and we therefore think the settings and findings of the study clinically relevant.

It is difficult to compare our findings to previously published data due to the injection regime being so different. It is even difficult to directly compare studies on GONB in headache as although widely used there is no set consensus on injection site, constituents and doses of the block, if the steroids should be used, the injection regime (single shot vs. repeated injections over a short period), the definitions of response and what headaches to treat²⁴. Similarly, it seems inappropriate to simply compare GONB response to MCNB response given all our patients had failed to show sustained response to routine GONB. However, as of yet, there is no other report on outcomes of multiple cranial nerve block injections given in both greater

and lesser occipital and trigeminal nerve territories and so we can only discuss in the context of GONB data, which is not ideal as acknowledged above.

In CCH, our group reported a 57% response to single GONB with median duration benefit of 21 days⁵. Placebo-controlled trials of GOB in CCH conducted by Ambrosini *et al.*¹⁵ and Leroux *et al.*¹⁶ reported 57% of those treated with steroids being pain free at four weeks compared to zero with placebo and 86% of cluster headache patients (14 CCH) receiving steroid showing a more than 50% reduction in attack frequency after two weeks versus 59% of placebo (a non-significant difference), respectively.

Two placebo-controlled trials on purely CM patients have been conducted to date. One found no difference in mean duration of headache-freedom between local anaesthetic (3.7 days) versus local anaesthetic and steroid injections (1.0 days) in 37 patients²⁰, yet another found that the active group had significantly greater reductions in headache days (around 9 days) compared to placebo (around 4 days) after one month¹⁹. Open-label studies of GONB in CM recorded response rates of 52% from Weibelt *et al.*⁹ and 48% by Afridi *et al.*³

For other phenotypes there is very little data and no controlled-trials. In SUNCT/SUNA, Pareja *et al.* found no responders to multiple nerve blocks¹³ (including SON, GON, stellate ganglion and retrobulbar targets) in seven patients whereas a case study from Porta-Etessam *et al.* described a positive outcome¹⁴. Hemicrania continua responded to GONB in 85% of patients in the Afridi *et al.* cohort³. In HC cohorts undergoing combinations of GON, LON and SON, Guerrero *et al.* reported all nine patients responding for between two and ten months¹². In a study examining the outcome of GON, LON and SON blocks in HC, Antonaci *et al.* found that 57% responded to SON blocks but zero to either GON or LON blocks¹¹. The evidence for peripheral nerve blocks in CPH consists of one small open-label series of six patients, none of whom responded to either GON, LON or SON blocks¹¹.

Given that our response rates to MCNB in patients already having failed to respond to GONB are similar to those quoted for the occipital blocks themselves, this suggests that MCNB have an efficacy in a more resistant patient group than that studied in the GONB literature. It would perhaps be a step too far to suggest that they may have greater efficacy than GONB alone in nerve block naive patients but it would be interesting to compare the procedures directly to ascertain if this is why they still have similar response rates to GONB despite their use in more refractory patient groups.

The issue of the placebo effect in injectable treatments must be considered when assessing the effect of MCNB and similar procedures. Although it is widely assumed that invasive treatments have a higher placebo rate than oral medication, the studies in headache on the placebo effect of injectable treatments is still lacking. In the studies mentioned above, different injection protocols and the use of lidocaine as a placebo all mean the placebo response to even GONB is unknown. In a meta-analysis of GONB in migraine, pooled results show that in terms of pain reduction GONB is significantly better than placebo, suggesting they do have a real treatment effect. However, the use of multiple injections may increase the placebo effect and this has to be considered when looking at the efficacy of treatments such as MCNB. Clinically, what is important for the patient, especially in complex and refractory groups, is if patients exhibit a useful benefit even if the placebo effect cannot be quantified. When the procedure does appear to be safe and well tolerated, a pragmatic approach should surely be applied to help highly disabled patients.

The adverse event profile of GONB in headache patients has been favourable with most cohorts reporting only minor adverse events of injection site pain, dizziness and neck pain being most

common. Our cohort found a very similar adverse event profile to those published in GONB despite the increase in injection sites.

It is important that transitional treatments work quickly and that is why we examined the effect of MCNB after two weeks. It is also important that any benefit is sustained, and this study shows that this is the case. Equally essential is a favourable adverse event profile and again, our data shows this. Furthermore, we show a reproducible effect in responders which may allow significant periods of relief from chronic headaches in patients failing to respond to standard GONB. As with GONB, the repeated use of MCNB avoids the cost and side effects of oral steroids, IV DHE or IV lidocaine.

In conclusion, our study suggests that MCNB can be rapidly efficacious in chronic headache providing reproducible benefit for a number of weeks even in those failing GONB. Our injection protocol appears to offer side effects comparable to GONB. We suggest that MCNB could be a useful addition to the transitional treatments already used for chronic headache.

Clinical implications

- Peripheral nerve blocks are widely employed in the transitional treatment of a wide variety of headache disorders
- Multiple cranial nerve blocks of the greater and lesser occipital nerves, auriculotemporal, supraorbital and supratrochlear nerves can be effective even in patients who have failed to respond to greater occipital nerve blocks alone
- The effects of multiple cranial nerve blocks can be rapid in onset and can last a number of weeks
- Side effects appear to be comparable to greater occipital nerve blocks

ACKNOWLEDGEMENTS:

We would like to thank our headache specialist nurses for their help with completion of the clinical database and management of the patients. We also thank the patients and their families for help with this project.

CONTRIBUTORS

Sarah Miller: Author. Analysed and interpreted data; drafted and revised the manuscript for intellectual content

Susie Lagrata: Author. Major role in acquisition of data; revised the manuscript for intellectual content

Manjit Matharu: Author. Design and conceptualised study, revised the manuscript for intellectual content

COMPETING INTERESTS:

SM has received educational and travel grants and payment for the development of educational presentations from St Jude Medical, Medtronic and Allergan

SL has received honoraria from Allergan and Novartis for attending advisory meetings and preparing educational material

MSM serves on the advisory board for Allergan, St Jude Medical, Medtronic and Eli Lilly and has received payment for the development of educational presentations from Abbott, Medtronic, Allergan and electroCore

STUDY FUNDING:

This study had no external funding source

REFERENCES

1. Bartsch T, Goadsby PJ. The trigeminocervical complex and migraine: current concepts and synthesis. *Curr Pain Headache Rep* 2003;7:371-376.
2. Ashkenazi A, Blumenfeld A, Napchan U, et al. Peripheral nerve blocks and trigger point injections in headache management - a systematic review and suggestions for future research. *Headache* 2010;50:943-952.
3. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes--prolonged effects from a single injection. *Pain* 2006;122:126-129.
4. Arner S, Lindblom U, Meyerson BA, Molander C. Prolonged relief of neuralgia after regional anesthetic blocks. A call for further experimental and systematic clinical studies. *Pain* 1990;43:287-297.
5. Lambru G, Abu Bakar N, Stahlhut L, et al. Greater occipital nerve blocks in chronic cluster headache: a prospective open-label study. *Eur J Neurol* 2014;21:338-343.
6. Gantenbein AR, Lutz NJ, Riederer F, Sandor PS. Efficacy and safety of 121 injections of the greater occipital nerve in episodic and chronic cluster headache. *Cephalalgia* 2012;32:630-634.
7. Peres MF, Stiles MA, Siow HC, Rozen TD, Young WB, Silberstein SD. Greater occipital nerve blockade for cluster headache. *Cephalalgia* 2002;22:520-522.
8. Tobin J, Flitman S. Occipital nerve blocks: when and what to inject? *Headache* 2009;49:1521-1533.
9. Weibelt S, Andress-Rothrock D, King W, Rothrock J. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome. *Headache* 2010;50:1041-1044.
10. Cittadini E, Goadsby PJ. Hemicrania continua: a clinical study of 39 patients with diagnostic implications. *Brain* 2010;133:1973-1986.
11. Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves. *Funct Neurol* 1997;12:11-15.
12. Guerrero AL, Herrero-Velazquez S, Penas ML, et al. Peripheral nerve blocks: a therapeutic alternative for hemicrania continua. *Cephalalgia* 2012;32:505-508.
13. Pareja JA, Kruszewski P, Sjaastad O. SUNCT syndrome: trials of drugs and anesthetic blockades. *Headache* 1995;35:138-142.
14. Porta-Etessam J, Cuadrado ML, Galan L, Sampedro A, Valencia C. Temporal response to bupivacaine bilateral great occipital block in a patient with SUNCT syndrome. *J Headache Pain* 2010;11:179.
15. Ambrosini A, Vandenheede M, Rossi P, et al. Suboccipital injection with a mixture of rapid- and long-acting steroids in cluster headache: a double-blind placebo-controlled study. *Pain* 2005;118:92-96.
16. Leroux E, Valade D, Taifas I, et al. Suboccipital steroid injections for transitional treatment of patients with more than two cluster headache attacks per day: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2011;10:891-897.
17. Dilli E, Halker R, Vargas B, et al. Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. *Cephalalgia* 2015;35:959-968.
18. Kashipazha D, Nakhostin-Mortazavi A, Mohammadianinejad SE, Bahadoram M, Zandifar S, Tarahomi S. Preventive effect of greater occipital nerve block on severity and frequency of migraine headache. *Glob J Health Sci* 2014;6:209-213.

19. Inan LE, Inan N, Karadas O, et al. Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study. *Acta Neurol Scand* 2015;132:270-277.
20. Ashkenazi A, Matro R, Shaw JW, Abbas MA, Silberstein SD. Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. *J Neurol Neurosurg Psychiatry* 2008;79:415-417.
21. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edn. *Cephalalgia* 2004;24:1-160.
22. Maximum Recommended Doses and Duration of Local Anesthetics [online]. Available at: <https://medicine.uiowa.edu/iowaprotocols/maximum-recommended-doses-and-duration-local-anesthetics>. Accessed 25 March 2019.
23. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. *Cephalalgia* 2008;28:484-495.
24. Blumenfeld A, Ashkenazi A, Napchan U, et al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches--a narrative review. *Headache* 2013;53:437-446.

	CCH (n=52)	CM (n=49)	SUNCT/SUNA (n=16)	NDPH (n=10)	HC (n=6)	PH (n=4)
Sex						
Male	30 (57.7%)	21 (42.9%)	3 (18.8%)	5 (50.0%)	0	3 (75.0%)
Female	22 (42.3%)	28 (57.1%)	13 (81.3)	5 (50.0%)	6 (100%)	1 (25.0%)
Age (SD)	47.98 (±10.74)	48.84 (±12.60)	45.69 (±12.99)	48.30 (±12.51)	57.33 (±9.56)	50.00 (±12.32)
Range	20-69	22-79	21-65	29-67	42-67	34-64
Number headache types						
1	43 (82.7%)	35 (71.4%)	7 (43.8%)	8 (80.0%)	5 (83.3%)	4 (100.0%)
2	8 (15.4%)	13 (26.5%)	8 (50.0%)	2 (20.0%)	1 (16.7%)	0
3	1 (1.9%)	1 (2.0%)	1 (6.3%)	0	0	0
Co-existent Phenotypes						
Chronic cluster headache	N/A	8 (16.3%)	1 (6.3%)	0	0	0
Chronic migraine	8 (15.4%)	N/A	6 (37.5%)	0	1 (16.7%)	0
SUNCT/SUNA	2 (3.8%)	6 (12.2%)	N/A	2 (20.0%)	0	0
HC	0	1 (2.0%)	0	0	N/A	0

NDPH	0	0	2 (12.5%)	N/A	0	0
PH	0	0	0	0	0	N/A
Duration chronic headache (years)	8.65 (\pm 6.03) 1-24	11.41 (\pm 10.45) 2-51	7.38 (\pm 5.13) 2-19	17.50 (\pm 7.85) 9-26	11.33 (\pm 7.09) 2-23	17.50 (\pm 7.85) 9-26
Laterality of attacks						
Strictly unilateral	41 (78.8%)	11 (22.4%)	12 (75.0%)	7 (70.0%)	5 (83.3%)	3 (75.0%)
Unilateral but side variable	11 (21.2%)	11 (22.4%)	4 (25.0%)	0	1 (16.7%)	1 (25.0%)
Bilateral	0	27 (55.1%)	0	3 (30.0%)	0	0
Previous medications	8.71 (\pm 3.73) 0-15	9.73 (\pm 3.69) 2-19	8.00 (\pm 2.21) 4-12	9.80 (\pm 2.86) 6-15	7.50 (\pm 3.27) 4-13	7.75 (\pm 3.77) 4-11
Number GONB in past	1.75 (\pm 0.98) 1-4	1.94 (\pm 1.77) 1-12	2.31 (\pm 2.21) 1-8	1.80 (\pm 2.20) 1-8	2.33 (\pm 1.75) 1-5	3.00 (\pm 2.82) 1-7
1	29 (55.8%)	27 (55.1%)	11 (68.8%)	8 (80.0%)	3 (50.0%)	2 (50.0%)
2	11 (21.2%)	12 (24.5%)	3 (18.8%)	1 (10.0%)	1 (16.7%)	0

	3	8 (15.4%)	4 (8.2%)	0	0	0	1 (25.0%)
	4	4 (7.7%)	5 (10.2%)	0	0	1 (16.7%)	0
	5+	0	1 (2.0%)	2 (12.6%)	1 (10.0%)	1 (16.7%)	1 (25.0%)
Response to first GONB							
	No response	18 (34.6%)	22 (44.9%)	8 (50.0%)	9 (90.0%)	2 (33.3%)	1 (25.0%)
	Response (more than 50% least 14 days)	8 (15.4%)	6 (12.2%)	0	0	1 (16.7%)	1 (25.0%)
	Partial response	21 (40.4%)	17 (34.7%)	3 (18.8%)	1 (10.0%)	1 (16.7%)	0
	Worsening	5 (9.6%)	4 (8.2%)	3 (18.8%)	0	2 (33.3%)	2 (50.0%)
Injection Site							
	Unilateral	43 (82.7%)	14 (28.6%)	8 (50.0%)	6 (60.0%)	4 (66.7%)	4 (100.0%)
	Bilateral	9 (17.3%)	35 (71.4%)	8 (50.0%)	4 (40.0%)	2 (33.3%)	0
Immediate side effects							
	Dizziness	9 (17.3%)	9 (18.3%)	2 (12.6%)	2 (20.0%)	1 (16.7%)	0 (0.0%)
	Blurred vision	7 (13.5%)	5 (10.2%)	1 (6.3%)	1 (10.0%)	1 (16.7%)	
	Injection site tenderness	1 (1.9%)	1 (2.0%)	0	0	0	
		1 (1.9%)	2 (4.1%)	0	1 (10.0%)	0	

Worsening/triggering headache	0	1 (2.0%)	1 (6.3%)	0	0	
Adverse Events	17 (32.7%)	13 (26.4%)	4 (25.0%)	6 (60.0%)	1 (16.7%)	2 (50.0%)
Neck pain	2 (3.8%)	1 (2.0%)	0	1 (10.0%)	0	0
Injection site tenderness	7 (13.5%)	6 (12.2%)	1 (6.3%)	2 (20.0%)	0	1 (25.0%)
Numbness over injection sites	1 (1.9%)	0	0	0	0	0
Worsening headaches	3 (5.8%)	4 (8.2%)	1 (6.3%)	4 (40.0%)	0	1 (25.0%)
Blurred vision	1 (1.9%)	0	0	0	0	0
Nausea	3 (5.8%)	1 (2.0%)	0	0	0	0
Dizziness	0	1 (2.0%)	2 (12.6%)	0	1 (16.7%)	0

CCH, chronic cluster headache; CM, chronic migraine; GONB, greater occipital nerve; HC, hemicrania continua; NDPH, New Daily Persistent Headache; PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting unilateral neuralgiform headache attacks with autonomic features

Table 1: Demographic details by headache phenotype

	Unilateral Procedure	Bilateral Procedure
Supraorbital nerve*	2ml	1ml each side
Supratrochlear nerve*	2ml	1ml each side
Auriculotemporal nerve: proximal* §	4ml	2ml each side
Auriculotemporal nerve: distal* §§	8ml	3ml each side
Greater Occipital nerve**	4ml	4ml each side
Lesser Occipital nerve*	2ml	1ml each side

*50:50 mixture of lidocaine 2% and bupivacaine 0.5%

** 80mg (2ml) methylprednisolone, lidocaine 2% (1ml), bupivacaine 0.5% (1ml)

§ proximal auriculotemporal nerve injections are the ones performed just above the root of the helix of the ear

§§ distal auriculotemporal injections are the ones performed superiorly to the level of the proximal ones

Table 2: Multiple cranial nerve block injection protocol

	Pre MCNB	Post MCNB	Mean change (95%CI)	p-value
CCH (N=36)				
Total headache days	13.89 (±0.66)	6.31 (±6.11)	7.58 (5.49, 9.67)	<0.001*
Pain Free days	0.11 (±0.66)	7.42 (±5.98)	-7.31 (-9.36, - 5.24)	<0.001*
Attack frequency	4.17 (±1.94)	0.83 (±1.02)	3.33 (2.78, 3.89)	<0.001*
Attack duration	1.21 (±0.96)	0.40 (±0.55)	0.81 (0.44, 1.16)	<0.001*
Attack severity (VRS)	7.69 (±1.75)	2.39 (±2.85)	5.31 (4.24, 6.36)	<0.001*
CM (N=24)				
Total headache days	13.63 (±1.05)	9.13 (±5.24)	4.50 (2.45, 6.55)	<0.001*
Pain Free days	0.26 (±0.91)	4.74 (±5.33)	-4.48 (-6.60, - 2.34)	<0.001*

Moderate-to-severe headache days	12.42 (±2.91)	2.38 (±2.63)	10.04 (8.61, 11.46)	<0.001*
Daily duration	16.95 (±3.61)	8.95 (±6.96)	8.00 (5.11, 10.88)	<0.001*
Daily severity (VRS)*	6.25 (±1.48)	2.13 (±1.51)	4.12 (3.29, 4.95)	<0.001*
Moderate-to-severe headache days	12.42 (±2.91)	6.04 (±4.85)	6.38 (4.25, 8.49)	<0.001*
Daily duration	16.95 (±3.61)	10.66 (±5.96)	6.29 (3.62, 8.96)	<0.001*
SUNCT/SUNA (N=9)				
Total headache days	14.00 (±0.00)	5.00 (±6.36)	9.00 (4.10, 13.89)	0.003*
Pain free days	0.00	8.78 (±6.18)	-8.78 (-13.52, -4.02)	0.003*
Attack frequency	30.22 (±28.78)	0.33 (±0.50)	29.89 (7.57, 52.19)	0.015*
Attack duration	0.12 (±0.18)	0.01 (±0.05)	0.10 (-0.01, 0.21)	0.068
Attack severity (VRS)*	9.33 (±0.86)	2.00 (±3.50)	7.33 (4.81, 9.85)	<0.001*

NDPH (n=1)				
Total headache days	14.00	14.00	N/A	N/A
Pain free days	0.00	0.00	N/A	N/A
Moderate-to-severe days	14.00	7.00	N/A	N/A
Attack duration	15.00	15.00	N/A	N/A
Daily severity (VRS)*	5.00	4.00	N/A	N/A
HC (n=5)				
Total headache days	13.83 (±0.44)	2.40 (±3.36)	11.40 (6.95, - 15.84)	0.002*
Pain Free days	0.20 (±0.45)	11.00 (±2.82)	-10.80 (-14.57, - 7.03)	0.001*
Moderate-to-severe headache days	11.20 (±3.89)	0.00 (±0.00)	11.20 (6.35, 16.04)	0.003*
Daily duration	14.40 (±3.64)	1.00 (±2.23)	13.40 (9.61, 17.18)	0.001*
Daily severity (VRS)*	6.40 (±1.81)	0.20 (±0.45)	6.20 (4.16, 8.24)	0.001*
PH (n=1)				

Total headache days	14.00	5.00	N/A	N/A
Pain Free days	0	9	N/A	N/A
Attack Frequency	4.00	0.00	N/A	N/A
Daily duration	0.30	0.12	N/A	N/A
Daily severity (VRS)*	8.00	1.00	N/A	N/A

CCH, chronic cluster headache; CI, confidence interval; CM, chronic migraine; HC, hemicrania continua; MCNB, Multiple cranial nerve block; N/A, data not available due to single responder; NDPH, New Daily Persistent Headache; PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting unilateral neuralgiform headache attacks with autonomic features; VRS, verbal response scale

Table 3: Outcome at two weeks for all headache types

RESPONDERS	Pre MCNB	Post MCNB	Mean change (95%CI)	p-value
CCH (N=36)				
Response rate after 4 (in those responding at 2 weeks)	88.9			
Total headache days	13.89 (±0.66)	6.67 (±6.01)	7.22 (5.12, 9.31)	<0.001
Pain Free days	0.11 (±0.66)	7.33 (±6.01)	-7.22 (-9.31, -5.12)	<0.001
Attack frequency	4.17 (±1.94)	1.11 (±1.11)	3.06 (2.47, 3.63)	<0.001
Attack duration	1.21 (±0.96)	0.42 (±0.58)	0.79(0.49, 1.08)	<0.001
Attack severity (VRS)	7.69 (±1.75)	3.03 (±2.97)	4.67 (3.58, 5.76)	<0.001
CM (N=24)				
Response rate after 4 (in those responding at 2 weeks)	50.0%			
Total headache days	13.63 (±1.05)	10.88 (±4.89)	2.75 (0.89, 4.60)	0.005

Pain Free days	0.26 (±0.91)	3.13 (±4.89)	-2.75 (-4.60, - 0.89)	0.005
Moderate-to-severe headache days	12.42 (±2.91)	6.04 (±4.85)	6.38 (4.25, 8.49)	<0.001
Daily duration	16.95 (±3.61)	10.66 (±5.96)	6.29 (3.62, 8.96)	<0.001
Daily severity (VRS)*	6.25 (±1.48)	3.33 (±2.25)	2.92 (1.86, 3.97)	<0.001
SUNCT/SUNA (N=9)				
Response rate after 4 (in those responding at 2 weeks)	100.0%			
Total headache days	14.00 (±0.00)	8.44 (±6.71)	5.56 (0.39, 10.71)	0.038
Pain free days	0.00	6.36 (±2.12)	-9.00 (-13.89, - 4.10)	0.003
Attack frequency	30.22 (±28.78)	4.56 (±5.38)	25.67 (3.75, 47.58)	0.027
Attack duration	0.12 (±0.18)	0.02 (±0.32)	0.10 (-0.21, 0.22)	0.094
Attack severity (VRS)*	9.33 (±0.86)	3.89 (±3.72)	5.44 (2.92, 7.96)	0.001

NDPH (n=1)				
Response rate after 4 week (in those responding at 2 weeks)	100.0%			
Total headache days	14.00	14.00	N/A	N/A
Pain free days	0.00	0.00	N/A	N/A
Moderate-to-severe headache days	14.00	14.00	N/A	N/A
Daily duration	15.00	16.00	N/A	N/A
Daily severity (VRS)*	5.00	5.00	N/A	N/A
HC (n=5)				
Response rate after 4 week (in those responding at 2 weeks)	80.0%			
Total headache days	13.83 (±0.44)	5.20 (±7.15)	8.60 (-0.67, 17.87)	0.062
Pain Free days	0.20 (±0.45)	8.80 (±7.15)	-8.60 (-17.87, 0.67)	0.062
Moderate-to-severe headache days	11.20 (±3.89)	1.80 (±4.02)	9.40 (0.20, 18.59)	0.047

Daily duration	14.40 (±3.64)	4.40 (±6.38)	10.00 (-2.13, 22.13)	0.084
Daily severity (VRS)*	6.40 (±1.81)	1.20 (±1.64)	5.20 (0.95, 9.45)	0.027
PH (n=1)				
Response rate after 4 week (in those responding at 2 weeks)	0.0%			
Total headache days	14.00	1.00	N/A	N/A
Pain Free days	0	13.00	N/A	N/A
Attack Frequency	4.00	0.00	N/A	N/A
Daily duration	0.30	0.00	N/A	N/A
Daily severity (VRS)*	8.00	0.00	N/A	N/A

CCH, chronic cluster headache; CI, confidence interval; CM, chronic migraine; HC, hemicrania continua; MCNB, Multiple cranial nerve block; N/A, data not available due to single responder; NDPH, New Daily Persistent Headache; PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting unilateral neuralgiform headache attacks with autonomic features; VRS, verbal response scale

Table 4: Outcomes after four weeks for all headache types

Figure 1: Sites of peripheral nerve blocks





Figure 2A and 2B: Response rates of MCNB by headache phenotypes


Figure 2a



CCH, chronic cluster headache; CM, chronic migraine; GONB, greater occipital nerve; HC, hemicrania continua; MCNB, multiple cranial nerve block; NDPH, New Daily Persistent Headache; PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting unilateral neuralgiform headache attacks with autonomic features

Figure 2A: Response rates after first MCNB by headache phenotype

Figure 2b



CCH, chronic cluster headache; CM, chronic migraine; GONB, greater occipital nerve; HC, hemicrania continua; MCNB, multiple cranial nerve block; NDPH, New Daily Persistent Headache; PH, paroxysmal hemicrania; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA short lasting unilateral neuralgiform headache attacks with autonomic features

Figure 2B: Response rates of repeated MCNB by headache phenotype

Legend Figure 2B

The average number of MCNB per phenotype was as follows: CCH 2.44 blocks (range 1-8); CM 2.67 blocks (range 1-8); SUNCT/SUNA 3.56 blocks (range 1-8); NDPH 1 block; PH 1 block. The number of patients undergoing repeated blocks was as follows: CCH 27; CM 17; SUNCT/SUNA 9; NDPH 0; HC 4; PH 0.